(Circulation. 2000;101:590.)
© 2000 American Heart Association, Inc.
Brief Rapid Communications |
A Randomized Comparison of Clopidogrel and Aspirin Versus Ticlopidine and Aspirin After the Placement of Coronary-Artery Stents
From Herz-Zentrum, Bad Krozingen, Germany.
Correspondence to Dr Heinz J. Büttner, Herz-Zentrum, 79189–Bad Krozingen, Germany.
Background—The introduction of an effective antiplatelet therapy with aspirin and ticlopidine after the placement of coronary-artery stents has decreased the risk of thrombotic stent occlusions (TSO) and hemorrhagic complications. However, the use of ticlopidine is limited by hematological and gastrointestinal adverse effects. The safety and efficacy of clopidogrel after stenting remains to be established.
Methods and Results—After successful coronary stenting during elective or emergency percutaneous transluminal coronary angioplasty, 700 patients with 899 lesions were randomly assigned to receive a 4-week course of either 500 mg ticlopidine (n=345) or 75 mg clopidogrel (n=355), in addition to 100 mg aspirin. All the following clinical events reflecting TSO were included in the prespecified primary cardiac endpoint: cardiac death, urgent target vessel revascularization, angiographically documented TSO, or nonfatal myocardial infarction within 30 days. The primary noncardiac endpoint was defined as noncardiac death, stroke, severe peripheral vascular or hemorrhagic events, or any adverse event resulting in discontinuation of study medication. Cardiac events occurred in 17 patients [11 (3.1%) with clopidogrel and 6 (1.7%) with ticlopidine (P=0.24)]. The primary noncardiac endpoint was observed in 16 patients (4.5%) assigned to receive clopidogrel versus 33 patients (9.6%) assigned to receive ticlopidine (P=0.01).
Conclusions—After the placement of coronary-artery stents in unselected patients, antiplatelet therapy with aspirin and clopidogrel seems to be comparably safe and effective as aspirin and ticlopidine. Noncardiac events were significantly reduced with clopidogrel.
Key Words: clopidogrel • ticlopidine • stents • thrombosis • prevention
This article has been cited by other articles:
 |
|
 |
|
  R. C. Becker, J. Scheiman, H. L. Dauerman, F. Spencer, S. Rao, M. Sabatine, D. A. Johnson, F. Chan, N. S. Abraham, E. M.M. Quigley, et al. Management of Platelet-Directed Pharmacotherapy in Patients With Atherosclerotic Coronary Artery Disease Undergoing Elective Endoscopic Gastrointestinal Procedures J. Am. Coll. Cardiol., December 8, 2009; 54(24): 2261 - 2276. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Kim, C. Daskalakis, S. C. Silvestry, M. P. Sheth, A. N. Lee, S. Adams, S. Hohmann, S. Medvedev, and D. J. Whellan Aspirin and clopidogrel use in the early postoperative period following on-pump and off-pump coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg., December 1, 2009; 138(6): 1377 - 1384. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gao, C. Ren, D. Li, and L. Li Clopidogrel and aspirin versus clopidogrel alone on graft patency after coronary artery bypass grafting. Ann. Thorac. Surg., July 1, 2009; 88(1): 59 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Chua and A. Ignaszewski Clopidogrel in acute coronary syndromes BMJ, April 14, 2009; 338(apr14_1): b1180 - b1180. [Full Text]
|
|
|
|
 |
|
 J. M. Ruiz-Nodar, F. Marin, J. Sanchez-Paya, J. A. Hurtado, J. Valencia-Martin, S. Manzano-Fernandez, V. Roldan, V. Perez-Andreu, F. Sogorb, M. Valdes, et al. Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation Eur. Heart J., April 2, 2009; 30(8): 932 - 939. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ang and E. Mahmud Monitoring oral antiplatelet therapy: is it justified? Therapeutic Advances in Cardiovascular Disease, December 1, 2008; 2(6): 485 - 496. [Abstract] [PDF]
|
|
|
|
 |
|
 R. A. Harrington, R. C. Becker, C. P. Cannon, D. Gutterman, A. M. Lincoff, J. J. Popma, G. Steg, G. H. Guyatt, and S. G. Goodman Antithrombotic Therapy for Non-ST-Segment Elevation Acute Coronary Syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 670S - 707S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Aradi, A. Konyi, L. Palinkas, T. Berki, T. Pinter, T. Tahin, I. Horvath, L. Papp, and A. Komocsi Thienopyridine Therapy Influences Late Outcome After Coronary Stent Implantation Angiology, May 1, 2008; 59(2): 172 - 178. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Rogacka, A. Chieffo, I. Michev, F. Airoldi, A. Latib, J. Cosgrave, M. Montorfano, M. Carlino, G. M. Sangiorgi, A. Castelli, et al. Dual antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients taking chronic oral anticoagulation. J. Am. Coll. Cardiol. Intv., February 1, 2008; 1(1): 56 - 61. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J. Am. Coll. Cardiol., August 14, 2007; 50(7): e1 - e157. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bode and M. Zehender The use of antiplatelet agents following percutaneous coronary intervention: focus on late stent thrombosis Eur. Heart J. Suppl., August 1, 2007; 9(suppl_D): D10 - D19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Shim, Y. S. Choi, Y. J. Oh, S. O. Bang, K. J. Yoo, and Y. L. Kwak Effects of preoperative aspirin and clopidogrel therapy on perioperative blood loss and blood transfusion requirements in patients undergoing off-pump coronary artery bypass graft surgery J. Thorac. Cardiovasc. Surg., July 1, 2007; 134(1): 59 - 64. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The Society of Thoracic Surgeons Blood Conservatio, V. A. Ferraris, S. P. Ferraris, S. P. Saha, E. A. Hessel II, C. K. Haan, B. D. Royston, C. R. Bridges, R. S.D. Higgins, G. Despotis, et al. Perioperative Blood Transfusion and Blood Conservation in Cardiac Surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists Clinical Practice Guideline Ann. Thorac. Surg., May 1, 2007; 83(5_Supplement): S27 - S86. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Eshaghian, S. Kaul, S. Amin, P. K. Shah, and G. A. Diamond Role of Clopidogrel in Managing Atherothrombotic Cardiovascular Disease Ann Intern Med, March 20, 2007; 146(6): 434 - 441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. Stone and H. D. Aronow Long-term Care After Percutaneous Coronary Intervention: Focus on the Role of Antiplatelet Therapy Mayo Clin. Proc., May 1, 2006; 81(5): 641 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-W. Lee, S.-W. Park, M.-K. Hong, Y.-H. Kim, B.-K. Lee, J.-M. Song, K. H. Han, C. W. Lee, D.-H. Kang, J.-K. Song, et al. Triple Versus Dual Antiplatelet Therapy After Coronary Stenting: Impact on Stent Thrombosis J. Am. Coll. Cardiol., November 15, 2005; 46(10): 1833 - 1837. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Wenaweser, O. M. Hess, and S. Windecker The management and prevention of thrombotic stent occlusion: reply Eur. Heart J., November 1, 2005; 26(21): 2345 - 2346. [Full Text] [PDF]
|
|
|
|
|
|
J.-Y. Leong, R. A. Baker, P. J. Shah, V. K. Cherian, and J. L. Knight Clopidogrel and Bleeding After Coronary Artery Bypass Graft Surgery Ann. Thorac. Surg., September 1, 2005; 80(3): 928 - 933. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Cannon, S. R. Mehta, and S. F. Aranki Balancing the Benefit and Risk of Oral Antiplatelet Agents in Coronary Artery Bypass Surgery Ann. Thorac. Surg., August 1, 2005; 80(2): 768 - 779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M.W. Bath, L. Zhao, and S. Heptinstall Current status of stroke prevention in patients with atrial fibrillation Eur. Heart J. Suppl., May 1, 2005; 7(suppl_C): C12 - C18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members, S. Silber, P. Albertsson, F. F. Aviles, P. G. Camici, A. Colombo, C. Hamm, E. Jorgensen, J. Marco, J.-E. Nordrehaug, et al. Guidelines for Percutaneous Coronary Interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology Eur. Heart J., April 2, 2005; 26(8): 804 - 847. [Full Text] [PDF]
|
|
|
|
|
|
R. Ascione, A. Ghosh, C. A. Rogers, A. Cohen, C. Monk, and G. D. Angelini In-Hospital Patients Exposed to Clopidogrel Before Coronary Artery Bypass Graft Surgery: A Word of Caution Ann. Thorac. Surg., April 1, 2005; 79(4): 1210 - 1216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Inoue, T. Uchida, M. Sakuma, Y. Imoto, Y. Ozeki, Y. Ozaki, Y. Hikichi, and K. Node Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation J. Am. Coll. Cardiol., October 6, 2004; 44(7): 1408 - 1414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Popma, P. Berger, E. M. Ohman, R. A. Harrington, C. Grines, and J. I. Weitz Antithrombotic Therapy During Percutaneous Coronary Intervention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 576S - 599S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. van der Heijden, I. C. D. Westendorp, R. K. Riezebos, F. Kiemeneij, T. Slagboom, L. R. van der Wieken, and G.-J. Laarman Lack of efficacy of clopidogrel pre-treatment in the prevention of myocardial damage after elective stent implantation J. Am. Coll. Cardiol., July 7, 2004; 44(1): 20 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Stadius Diminishing returns ...and too many choices ...the saga of pharmacologic therapy to reduce the complications of percutaneous coronary intervention J. Am. Coll. Cardiol., July 7, 2004; 44(1): 25 - 27. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Englberger, B. Faeh, P. A. Berdat, F. Eberli, B. Meier, and T. Carrel Impact of clopidogrel in coronary artery bypass grafting Eur. J. Cardiothorac. Surg., July 1, 2004; 26(1): 96 - 101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Jneid, D. L. Bhatt, R. Corti, J. J. Badimon, V. Fuster, and G. S. Francis Aspirin and Clopidogrel in Acute Coronary Syndromes: Therapeutic Insights From the CURE Study Arch Intern Med, May 26, 2003; 163(10): 1145 - 1153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Matsagas, I. A. Jagroop, G. Geroulakos, and D. P. Mikhailidis The Effect of a Loading Dose (300 mg) of Clopidogrel on Platelet Function in Patients with Peripheral Arterial Disease Clinical and Applied Thrombosis/Hemostasis, April 1, 2003; 9(2): 115 - 120. [Abstract] [PDF]
|
|
|
|
|
|
C. Mueller, H. Roskamm, F.-J. Neumann, P. Hunziker, S. Marsch, A. Perruchoud, and H. J. Buettner A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents J. Am. Coll. Cardiol., March 19, 2003; 41(6): 969 - 973. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Niccoli and A P Banning Heparin dose during percutaneous coronary intervention: how low dare we go? Heart, October 1, 2002; 88(4): 331 - 334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H. Hongo, J. Ley, S. E. Dick, and R. R. Yee The effect of clopidogrel incombination with aspirin whengiven before coronary artery bypass grafting J. Am. Coll. Cardiol., July 17, 2002; 40(2): 231 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Izaguirre-Avila, A. D. l. Penia-Diaz, F. Barinagarrementeria-Aldatz, H. Gonzailez-Pacheco, A. E. Ramirez-Gutierrez, J. L. Ruiz-Sandoval, A. Quiroz-Martinez, and C. Cantu-Brito Effect of Clopidogrel on Platelet Aggregation and Plasma Concentration of Fibrinogen in Subjects with Cerebral or Coronary Atherosclerotic Disease Clinical and Applied Thrombosis/Hemostasis, April 1, 2002; 8(2): 169 - 177. [Abstract] [PDF]
|
|
|
|
|
|
D. L. Bhatt, M. E. Bertrand, P. B. Berger, P. L. L'Allier, I. Moussa, J. W. Moses, G. Dangas, M. Taniuchi, J. M. Lasala, D. R. Holmes, et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting J. Am. Coll. Cardiol., January 2, 2002; 39(1): 9 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Taniuchi, H. I. Kurz, and J. M. Lasala Randomized Comparison of Ticlopidine and Clopidogrel After Intracoronary Stent Implantation in a Broad Patient Population Circulation, July 31, 2001; 104(5): 539 - 543. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Schuhlen, A. Kastrati, J.u. Pache, J. Dirschinger, and A. Schomig Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen J. Am. Coll. Cardiol., June 15, 2001; 37(8): 2066 - 2073. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Smith Jr, J. T. Dove, A. K. Jacobs, J. Ward Kennedy, D. Kereiakes, M. J. Kern, R. E. Kuntz, J. J. Popma, H. V. Schaff, D. O. Williams, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines): A report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions J. Am. Coll. Cardiol., June 15, 2001; 37(8): 2239 - 2239. [Full Text] [PDF]
|
|
|
|
|
|
D. L. Bhatt, D. P. Chew, A. T. Hirsch, P. A. Ringleb, W. Hacke, and E. J. Topol Superiority of Clopidogrel Versus Aspirin in Patients With Prior Cardiac Surgery Circulation, January 23, 2001; 103(3): 363 - 368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Patrono, B. Coller, J. E. Dalen, G. A. FitzGerald, V. Fuster, M. Gent, J. Hirsh, and G. Roth Platelet-Active Drugs : The Relationships Among Dose, Effectiveness, and Side Effects Chest, January 1, 2001; 119 (2009): 39S - 63S. [Full Text] [PDF]
|
|
|
|
|
|
J. J. Popma, E. M. Ohman, J. Weitz, A. M. Lincoff, R. A. Harrington, and P. Berger Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention Chest, January 1, 2001; 119 (2009): 321S - 336S. [Full Text] [PDF]
|
|
|
|
|
|
The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme. Rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease Eur. Heart J., December 2, 2000; 21(24): 2033 - 2041. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Al Suwaidi, P. B. Berger, and D. R. Holmes Jr Coronary Artery Stents JAMA, October 11, 2000; 284(14): 1828 - 1836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Braunwald, E. M. Antman, J. W. Beasley, R. M. Califf, M. D. Cheitlin, J. S. Hochman, R. H. Jones, D. Kereiakes, J. Kupersmith, T. N. Levin, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-st-segment elevation myocardial infarction: A report of the american college of cardiology/ american heart association task force on practice guidelines (committee on the management of patients with unstable angina) J. Am. Coll. Cardiol., September 1, 2000; 36(3): 970 - 1062. [Full Text] [PDF]
|
|